Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer

Joseph Califano*, Andrew Yousef, Heba Mostafa, Alexandra Valsamakis, Xinlian Zhang, Nikolaos Batis, Christy Varghese, Joanna Parish, Michael Forman, Junko Jarrett, Karen Messer, Hisham Mehanna*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

49 Downloads (Pure)

Abstract

IMPORTANCE: Head and neck squamous cell carcinoma is a highly lethal cancer that is often associated with human papillomavirus (HPV). Recent studies have shown promise in the use of HPV DNA detection in salivary rinses and plasma as a factor associated with a future diagnosis of HPV-positive oropharynx cancer (HPVOPC). However, the use of plasma and salivary HPV DNA detection in defining risk for recurrence in the context of a prospective, phase 3, clinical trial coupled with standardized clinical surveillance has not been reported.

OBJECTIVE: To identify patients with low-risk HPVOPC at risk for recurrence by detection of HPV16 DNA in plasma and salivary rinses.

DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, 233 low-risk patients were recruited from 32 head and neck treatment centers in Ireland (1 [3.1%]), the Netherlands (1 [3.1%]), and the UK (30 [93.8%]) as part of the DE-ESCALATE HPV trial, an open-label, phase 3 randomized clinical trial examining treatment with cetuximab vs cisplatin for HPVOPC. Patients were assayed for the presence of HPV16 DNA in plasma and salivary rinse via a quantitative polymerase chain reaction-based assay.

MAIN OUTCOMES AND MEASURES: Assay results were associated with risk of recurrence and lead time from HPV16 DNA detection to recurrence.

RESULTS: Of 233 patients, 45 (19.3%) were women, and the mean (SD) age was 57.01 (8.45) years. A total 1040 salivary or blood samples were collected during the course of the study. With a median follow-up of 760 days, the sensitivity and specificity of combined plasma and salivary rinse HPV DNA assays for detecting recurrence were 65% and 87%, respectively. There was a median lead time of positive test to event/recurrence date of 19 days (range, 0-536 days) and mean (SD) of 122 (169.8) days.

CONCLUSION AND RELEVANCE: The results of this cohort study suggest that in the setting of a randomized, prospective, phase 3 trial for low-risk patients with HPVOPC, posttreatment presence of HPV DNA in plasma and salivary rinses is associated with recurrence; a lead time between test positivity and clinical recurrence offers a potential opportunity for earlier detection of recurrence.

Original languageEnglish
Pages (from-to)812-819
Number of pages8
JournalJAMA Otolaryngology - Head and Neck Surgery
Volume149
Issue number9
Early online date27 Jul 2023
DOIs
Publication statusPublished - 1 Sept 2023

Fingerprint

Dive into the research topics of 'Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer'. Together they form a unique fingerprint.

Cite this